

Wild Type Melanoma Metastatic Melanoma Skin Cancer

**A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases**

**Trial Status**  
Completed

**Trial Runs In**  
8 Countries

**Trial Identifier**  
NCT03625141 2018-000759-41  
MO39136

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This study will evaluate the efficacy and safety of cobimetinib plus atezolizumab in participants with BRAFV600 wild-type melanoma with central nervous system (CNS) metastases and of cobimetinib plus atezolizumab and vemurafenib in BRAFV600 mutation-positive melanoma patients with CNS metastases.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT03625141 2018-000759-41 MO39136**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 18 Years

**Healthy Volunteers**  
No

---